Navigation Links
Bayer HealthCare Introduces First Mobile Application to Assist Hemophilia A Patients in Managing Their Treatment
Date:6/28/2010

WAYNE, N.J., June 28 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today launched FactorTrack™, the first customizable mobile application for people with hemophilia A.  FactorTrack is a free, personal and interactive mobile application that helps make it easier to track and record hemophilia factor VIII infusions.  

FactorTrack captures dosing history, frequency and locations of bleeds.  It allows people with hemophilia A to customize their infusion schedule based on their prescribed regimen, view their infusion history and, with an Internet connection, display an alert when it's time for the next infusion.  It also gives patients the option of emailing infusion and bleed history to themselves or their healthcare team if email is configured on their device.  Further, FactorTrack links people with hemophilia A to educational tools and online resources.  

Any person who treats his or her bleeds with factor VIII infusions can use FactorTrack, regardless of the specific product or therapy.  For those on a prophylaxis (preventive) regimen, the application offers a reminder system to help make it easier to remember when to infuse.  For those who infuse factor VIII on demand (when needed), the application serves as a diary to record bleeds and infusions.  

"FactorTrack is the latest innovation from Bayer that illustrates our ongoing commitment to helping enhance the lives of people who live with bleeding disorders," said Paul Bedard, vice president and general manager, Hematology, Bayer HealthCare Pharmaceuticals Inc.  "We worked alongside the hemophilia community, physical therapists and physical educators to develop the application in response to the needs of people with hemophilia A."

Designed to be compatible with a number of smart phone platforms, FactorTrack is available today on an iPhone, iPod touch or iPad.  People can get information about downloading FactorTrack by going to LivingWithHemophilia.com/FactorTrack.  In the near future, FactorTrack will be made available on other smart phones and the Web.

Bayer doesn't collect personal information when people use the FactorTrack application.  People can use the application without entering information that identifies them.  Recorded data are completely private and will only be stored on a personal iPhone or iPod touch.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals operation of Bayer HealthCare, an affiliate of Bayer AG.  One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology, and Oncology.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER and the Bayer Cross are registered trademarks and FactorTrack is a trademark of Bayer.

iPhone and iPod touch are registered trademarks and iPad is a trademark of Apple.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
2. Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Tevas Generic Oral Contraceptive Gianvi™
3. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
4. Bayer Diabetes Care Introduces DIDGET In the US
5. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
6. Bayers A1CNow(R) SELFCHECK At-Home A1C System Now Available In Local Pharmacies
7. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
8. Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels
9. Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced
10. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
11. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... ... , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care ... on preventative care with all my patients to alleviate possible future issues. I am pleased ... contact my office and my trained staff will assist you in any way possible.” , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):